Evidence map›Paper›PMID 40579412›Full record

ArticleNature communications2025

Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia.

Julia Costea, Kerstin K Rauwolf, Pietro Zafferani, Tobias Rausch, Anna Mathioudaki, Judith Zaugg, Martin Schrappe, Cornelia Eckert, Gabriele Escherich, Jean P Bourquin and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Thieno[3,2-International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julia Costea *Molecular Medicine Partnership Unit (MMPU), EMBL and Medical Faculty of Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-7942-4495
Kerstin K Rauwolf *Division of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland.
Pietro ZafferaniEuropean Molecular Biology Laboratory (EMBL), Genome Biology Unit, Heidelberg, Germany.ORCID http://orcid.org/0009-0006-2428-7618
Tobias RauschMolecular Medicine Partnership Unit (MMPU), EMBL and Medical Faculty of Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5773-5620
Anna MathioudakiMolecular Medicine Partnership Unit (MMPU), EMBL and Medical Faculty of Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-4617-7015
Judith ZauggMolecular Medicine Partnership Unit (MMPU), EMBL and Medical Faculty of Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8324-4040
Martin SchrappeDepartment of Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Cornelia EckertDepartment of Pediatric Oncology/Hematology, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID http://orcid.org/0000-0003-1039-2872
Gabriele EscherichClinic of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jean P BourquinDivision of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland.ORCID http://orcid.org/0000-0001-6571-6227
Beat BornhauserDivision of Pediatric Oncology, University Children's Hospital, Zürich, Switzerland.ORCID http://orcid.org/0000-0003-2890-3191
Andreas E KulozikMolecular Medicine Partnership Unit (MMPU), EMBL and Medical Faculty of Heidelberg University, Heidelberg, Germany. andreas.kulozik@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-1953-0848
Jan O KorbelMolecular Medicine Partnership Unit (MMPU), EMBL and Medical Faculty of Heidelberg University, Heidelberg, Germany. jan.korbel@embl.de.ORCID http://orcid.org/0000-0002-2798-3794

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-ALL relapses are characterized by chemotherapy resistance, cellular diversity and dismal outcome. To gain a deeper understanding of the mechanisms underlying relapses, we conduct single-cell RNA sequencing on 13 matched pediatric T-ALL patient-derived samples at diagnosis and relapse, along with samples derived from 5 non-relapsing patients collected at diagnosis. This comprehensive longitudinal single-cell study in T-ALL reveals significant transcriptomic diversity. Notably, 11 out of 18 samples exhibit a subpopulation of T-ALL cells with stem-like features characterized by a common set of active regulons, expression patterns and splice isoforms. This subpopulation, accounting for a small proportion of leukemia cells at diagnosis, expands substantially at relapse, indicating resistance to therapy. Strikingly, increased stemness at diagnosis is associated with higher risk of treatment induction failure. Chemotherapy resistance is validated through in-vitro and in-vivo drug testing. Thus, we report the discovery of treatment-resistant stem-like cells in T-ALL, underscoring the potential for devising future therapeutic strategies targeting stemness-related pathways.

Indexed as

Drug Resistance, NeoplasmNeoplastic Stem CellsPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAdolescentAnimalsCell Line, TumorChildChild, PreschoolFemaleGene Expression Regulation, LeukemicHumansMaleMiceNeoplasm Recurrence, LocalRecurrenceSingle-Cell Analysis

Identifiers

PMID40579412
PMCPMC12205070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.